Pfizer (PFE): Price Target and June Short Interest Disclosure

Pfizer (PFE) has been rated by 13 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $54 and the lowest price target forecast is $33. The average forecast of all the analysts is $38.92 and the expected standard deviation is $5.56.

Pfizer (PFE) stated loss of 5,275,916 shares or 9.4% in the short interest. The short interest registered from 55,944,798 on June 15,2016 to 50,668,882 on June 30,2016. In terms of floated shares, the shorted positions stood at 0.8%. The stock has been averaging 27,487,771 shares daily in trading and would need 2 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, Jefferies maintains their rating on the shares of Pfizer (NYSE:PFE). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $40 per share from $42 per share. The rating by the firm was issued on June 20, 2016.


Pfizer (NYSE:PFE): stock turned positive on Thursday. Though the stock opened at $36.49, the bulls momentum made the stock top out at $36.96 level for the day. The stock recorded a low of $36.25 and closed the trading day at $36.92, in the green by 1.68%. The total traded volume for the day was 27,661,388. The stock had closed at $36.31 in the previous days trading.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.